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BACKGROUND: Statins are effective lipid-lowering drugs
for the prevention of cardiovascular disease, but muscu-
lar adverse events can limit their use. Hydrophilic statins
(pravastatin, rosuvastatin) may cause less muscular
events than lipophilic statins (e.g. simvastatin, atorva-
statin) due to lower passive diffusion into muscle cells.
OBJECTIVE: To compare the risk of muscular events
between statins at comparable lipid-lowering doses and
to evaluate if hydrophilic statins are associated with a
lower muscular risk than lipophilic statins.
DESIGN/SETTING: Propensity score-matched cohort
study using data from the United Kingdom-based Clinical
Practice Research Datalink (CPRD) GOLD.
PATIENTS:New statin users. Cohort 1: pravastatin 20-40
mg (hydrophilic) vs simvastatin 10-20 mg (lipophilic), co-
hort 2: rosuvastatin 5-40mg (hydrophilic) vs atorvastatin
10-80mg (lipophilic), and cohort 3: simvastatin 40-80mg
vs atorvastatin 10-20 mg.
MAIN MEASURES: The outcome was a first record of a
muscular event (myopathy,myalgia, myositis, rhabdomy-
olysis) during a maximum follow-up of 1 year.
KEY RESULTS: The propensity score-matched cohorts
consisted of 1) 9,703, 2) 7,032, and 3) 37,743 pairs of
statin users. Comparing the risk of muscular events be-
tween low-intensity pravastatin vs low-intensity simva-
statin yielded a HR of 0.86 (95% CI 0.64-1.16). In the
comparison of moderate- to high-intensity rosuvastatin
vs equivalent doses of atorvastatin, we observed a HR of
1.17 (95%CI 0.88-1.56). Moderate- to high-intensity sim-
vastatin was associated with a HR of 1.33 (95% CI 1.16-
1.53), when compared with atorvastatin at equivalent
doses.
LIMITATIONS:We could not conduct other pairwise com-
parisons of statins due to small sample size. In the ab-
sence of a uniform definition on the comparability of stat-
in doses, the applied dose ratios may not fully match with
all literature sources.
CONCLUSIONS: Our results do not suggest a systemati-
cally lower risk of muscular events for hydrophilic statins
when compared to lipophilic statins at comparable lipid-
lowering doses.
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INTRODUCTION
Statins are effective lipid-lowering drugs for the primary and
secondary prevention of ischemic cardiovascular events.1, 2
Although generally well tolerated, statins may cause myalgia,
and less frequently myositis or rhabdomyolysis.3 According to
randomized controlled trials (RCTs), 1.5–5.0% of patients
experience adverse muscular symptoms during statin treat-
ment.4 However, observational studies suggested that in rou-
tine care up to 10–15% of statin users experience such adverse
events.2, 4
The myotoxicity of statins appears to be dose-dependent
and may differ across individual statins,5, 6 as suggested by the
market withdrawal of cerivastatin due to its pronounced risk of
rhabdomyolysis.7 It has been hypothesized that hydrophilic/
water-soluble statins (i.e., rosuvastatin and pravastatin) are
less likely to cause muscular side effects than lipophilic/fat-
soluble statins (e.g., simvastatin or atorvastatin) due to lower
passive diffusion into muscle cells.8, 9 This hypothesis is
supported by in vitro data showing a higher cytotoxicity on
C2C12 myotubes for lipophilic statins than hydrophilic
statins.10
Results from RCTs, however, suggest a similar muscular
risk for hydrophilic and lipophilic statins at comparable lipid-
lowering doses, but the absolute numbers of events in these
trials were low.11, 12 More comprehensive and robust data on
the comparative muscular risks of statins at equivalent doses
are needed to improve our understanding of the role of statin
choice for the risk of such adverse events.
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We aimed to compare the risk of muscular events between
statins at comparable lipid-lowering doses, and to evaluate if
hydrophilic statins are associated with a systematically lower
risk of muscular events than lipophilic statins.
METHODS
Study Design and Data Resource
We conducted an observational cohort study using data from
the United Kingdom-based Clinical Practice Research
Datalink (CPRD) GOLD. CPRD GOLD is a primary care
database13 that contains anonymized longitudinal electronic
medical records on more than 15 million patients.14, 15 The
data held in the CPRD GOLD are collected in general prac-
tices as part of routine care.15 Data on demographics, medical
diagnoses or symptoms (using “Read codes”), or lifestyle
factors are available. CPRD GOLD contains comprehensive
and detailed information on drug prescriptions, including
product name, dose, number of tablets, and prescription
date.15
The study protocol was approved by the Independent Sci-
entific Advisory Committee for Medicines and Healthcare
Products Regulatory Agency database research (protocol no.
19_052) and has been made available to the journal editors.
Study Population
We identified all patients in CPRDGOLD aged 40 to 80 years
with a first statin prescription between January 2000 and
December 2017. Of these, we selected all patients with a first
prescription for hydrophilic pravastatin 20–40mg, hydrophilic
rosuvastatin 5–40 mg, lipophilic atorvastatin 10–80 mg, or
lipophilic simvastatin 10–80 mg who did not have any of the
following exclusion criteria at the cohort entry date (CED),
defined as date of the first statin prescription: (i) < 3 years of
medical records in CPRD GOLD; (ii) prior record of rhabdo-
myolysis, myositis, or myopathy (except myalgia, muscle
ache, or muscle pain); (iii) prior diagnosis of a primary muscle
disorder, myoneural disorder, or a disorder associated with
muscle pain (e.g., polymyalgia rheumatica, fibromyalgia);
and/or (iv) any diagnosis of cancer (except non-melanoma
skin cancer), alcoholism or other substance abuse, or HIV.
To minimize heterogeneity in patient frailty, we categorized
patients into two groups of (i) primary or (ii) secondary
prevention of cardiovascular disease. Those with a diagnosis
of myocardial infarction or ischemic stroke before the CED
were classified as secondary prevention. All others were clas-
sified as primary prevention. Within each of the two groups,
we established 3 cohorts (6 cohorts in total) to conduct
pairwise comparisons of statins at comparable lipid-lowering
doses: cohort 1—new users of pravastatin 20–40 mg vs sim-
vastatin 10–20 mg (low-intensity statin therapy); cohort
2—new users of rosuvastatin 5–40 mg vs atorvastatin 10–80
mg; and cohort 3—new users of simvastatin 40–80 mg vs
atorvastatin 10–20 mg (moderate- to high-intensity statin ther-
apy).We could not conduct other pairwise comparisons due to
small sample size. We based comparability of doses on na-
tional guidelines in the UK.1 Because rosuvastatin was only
launched in the UK in March 2003,16 the CED of atorvastatin
users in cohort 2 had to be at or after that date. New users of
atorvastatin 10–20 mg may have been included in cohorts 2
and 3.
Statin Exposure Measurement and Follow-up
We followed patients in an “as treated” approach from the day
after CED for a maximum of 1 year or until the occurrence of
an outcome (muscular event). We censored patients 90 days
after statin discontinuation (no prescription re-fill for the study
drug within 90 days after the estimated end date of statin
supply17), on the day of treatment switch (prescription for a
type of statin other than the study drug), death, disenrollment
from CPRD GOLD, the day of a recorded exclusion criterion,
a recording of statin intolerance (if not classified as outcome,
see below), or at the end of the study period (December 31,
2017). We introduced the 90-day grace period for censoring
after statin discontinuation to account for potentially delayed
recording of outcomes. We calculated the supply of a statin
prescription based on the prescribed number of tablets and on
an assumed regimen of 1 tablet per day.
Study Outcome
The outcome of interest was a muscular event, defined as a
recorded Read code for (i) myopathy (proximal, drug-induced,
or toxic), myalgia (including “muscle pain” or “muscle ache”),
myositis, rhabdomyolysis, or unspecified muscle disorder, or
(ii) statin intolerance, if followed by a Read code listed under
(i) within 90 days (N = 32). Read codes are listed in Appendix
Table 1.
Covariates
We assessed 42 baseline covariates7, 18–21 before the CED
including demographics, lifestyle factors, body mass index,
comorbidities, comedication, health care utilization, and the
initially prescribed statin dose (Appendix Table 2).
Statistical Analysis
Within each of the 6 cohorts, we performed propensity score
(PS) matching, which is an established method to control for
confounding by balancing assessed baseline covariates be-
tween comparison groups.22, 23 Assessed baseline covariates
were potential confounders or predictors of the risk of muscu-
lar events.22 For each patient, we calculated a PS, i.e., the
predicted probability of receiving the statin of interest over the
comparator statin based on all assessed baseline covariates,
using multivariable logistic regression (dependent variable:
treatment group; predictor variables: assessed baseline covar-
iates). To account for potential bias due to changes in statin
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prescribing practice over time,1, 24, 25 we calculated calendar
time-specific PS, i.e., performed PS calculation separately
within 2-year time intervals, each including the patients with
a CED during that time period.26 We matched users of a statin
of interest 1:1 to users of a comparator statin with a compara-
ble PS within the 2-year time interval, applying a greedy 5-to-
1 digit matching algorithm. This algorithm initially matches
on 5 digits of the PS and, in each iteration, on a further reduced
number of digits to match the previously unmatched statin
users. Statin users who could not be matched were excluded. It
has been shown that treatment groups with the same distribu-
tion of propensity scores have the same distribution of all
assessed baseline covariates.27 Covariate balance before and
after PS matching was assessed using absolute standardized
differences (ASD). We defined covariate balance as an ASD
<10%.28 We plotted Kaplan-Meier curves in the matched
cohorts and performed Cox proportional hazard analyses to
calculate hazard ratios (HRs) with 95% confidence intervals
(CIs). As part of the primary analysis, we calculated time-
specific HRs for the follow-up periods of 1 to 30 days, 31 to 90
days, 91 to 180 days, and 181 to 365 days in the primary
prevention cohorts.
We performed subgroup analyses by sex, age, and initial
daily statin dose and conducted sensitivity analyses restricted
to patients with (i) no muscle complaints before the CED and
(ii) no use of CYP3A4 inhibiting drugs. CYP3A4-mediated
interactions with simvastatin and atorvastatin have been de-
scribed as a clinically relevant cause of muscular adverse
events.7, 29, 30 In further analyses, we (i) additionally censored
for change in statin dose and (ii) applied a broader outcome
definition including all “statin intolerance” records. Finally,
we repeated our analyses as multivariable regression analyses.
Appendix Table 3 provides further information on the addi-
tionally performed analyses. We conducted the majority of
additional analyses only in the primary prevention cohorts due
to the small sample size of the secondary prevention cohorts.
All analyses were conducted using SAS version 9.4 (SAS
Institute, Cary, NC, USA).
RESULTS
Cohort Characteristics
We identified 553,178 eligible statin initiators, of which we
grouped 469,860 (84.9%) patients into the primary prevention
group and 83,318 (15.1%) patients into the secondary preven-
tion group (Appendix Figure 1). In the primary prevention
group, we obtained the following PS-matched cohorts: (i)
9,703 pairs of pravastatin 20–40 mg vs simvastatin 10–20
mg, (ii) 7,032 pairs of rosuvastatin 5–40 mg vs atorvastatin
10–80 mg, and (iii) 37,743 pairs of simvastatin 40–80 mg vs
atorvastatin 10–20 mg. The corresponding cohorts in the
secondary prevention group included (iv) 4,121, (v) 836, and
(vi) 6,716 pairs.
In all 6 cohorts, covariate balance was achieved after PS
matching (Table 1, Appendix Tables 4–7; censoring reasons
after PS matching in Table 2 and Appendix Table 8). Kaplan
Meier plots for the primary prevention cohorts are displayed in
Appendix Figure 2. Sample size, covariate distribution, and
censoring reasons for the cohorts before PS matching are
shown in the Appendix Tables 4–10.
COMPARATIVE SAFETY
Primary Prevention Group
Low-Intensity Statin Therapy Pravastatin (hydrophilic) vs
simvastatin (lipophilic). After PS matching, the incidence
rate (IR) of muscular events was 10.8 per 1000 person-years
(PYs) in pravastatin users and 12.5 per 1000 PYs in simva-
statin users (Table 3). The overall HR for the risk of muscular
events was 0.86 (95% CI 0.64–1.16) for pravastatin use com-
pared with simvastatin use, which was driven by low HRs
between days 1–30 (HR 0.60, 95% CI 0.26–1.37) and days
31–90 (HR 0.60, 95% CI 0.32–1.11) of follow-up. After day
90, HRs attenuated to a null result (Table 4 and Appendix
Figure 3). Results were not meaningfully different within
subgroups by age and statin dose. The HR was higher in
women (0.99, 95% CI 0.67–1.47) than men (HR 0.73, 95%
CI 0.47–1.14). The overall result did not change materially
after restriction to statin users without concomitant use of
CYP3A4 inhibitors, restriction to patients with no muscle
complaints before the CED, and additional censoring for
change in statin dose. When we applied the broader outcome
definition including all records of “statin intolerance,” the HR
decreased to 0.70 (95% CI 0.54–0.91) (Table 5). Findings
from the multivariable regression analyses were similar to
those obtained in the PS-matched cohort (Appendix Table 11).
Moderate- to High-Intensity Statin Therapy. Rosuvastatin
(hydrophilic) and simvastatin (lipophilic) vs atorvastatin (li-
pophilic). In the PS-matched cohort of rosuvastatin vs atorva-
statin, IRs of muscular events were 17.8 and 15.2 per 1000
PYs, and in the PS-matched cohort of simvastatin vs atorva-
statin, they were 16.5 and 12.4 per 1000 PYs, respectively
(Table 3). The overall HR was 1.17 (95% CI 0.88–1.56) for
rosuvastatin compared with atorvastatin and 1.33 (95% CI
1.16–1.53) for simvastatin compared with atorvastatin. In both
cohorts, the HRwas highest during the first 90 days of follow-
up, and attenuated towards the null thereafter. The highest
HRs, with atorvastatin as the referent, were 1.43 (95% CI
0.82–2.50) for rosuvastatin between days 31–90 of follow-
up, and 1.91 (95%CI 1.29–2.81) for simvastatin between days
1–30 of follow-up (Table 4 and Appendix Figure 3). Results
of subgroup, sensitivity, and additional analyses were not
meaningfully different from the overall result in both cohorts
(Table 5). Results from the multivariable regression analyses
were consistent with the findings obtained in the PS-matched
cohorts (Appendix Table 11).
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Table 1 Baseline Covariates by Treatment Group in the Primary Prevention Cohorts of Pravastatin vs Simvastatin and Rosuvastatin vs
Atorvastatin After Propensity Score Matching (Simvastatin vs Atorvastatin in Appendix Table 4)










Age (years), mean (SD) 63.1 (9.8) 63.0 (9.8) 1.1 61.0 (9.9) 61.1 (9.9) −1.0
Male, n (%) 4,887 (50.4) 4,960 (51.1) −1.5 3,411 (48.5) 3,364 (47.8) 1.3
Current smoker*, n (%) 1,950 (20.1) 2,009 (20.7) −1.5 1,376 (19.6) 1,321 (18.8) 2.0
>14 alcohol units/week*, n (%) 809 (8.3) 824 (8.5) −0.6 709 (10.1) 698 (9.9) 0.5
Obesity*, n (%) 2,531 (26.1) 2,547 (26.2) −0.4 2,104 (29.9) 2,109 (30.0) −0.2
Comorbidities, n (%)—at any time before the cohort entry date, if not specified otherwise
Hyperlipidemia 4,912 (50.6) 4,867 (50.2) 0.9 4,877 (69.4) 4,916 (69.9) −1.2
Diabetes mellitus 2,097 (21.6) 2,165 (22.3) −1.7 1,505 (21.4) 1,497 (21.3) 0.3
Hypertension 4,750 (49.0) 4,754 (49.0) −0.1 3,614 (51.4) 3,663 (52.1) −1.4
Heart failure 400 (4.1) 375 (3.9) 1.3 116 (1.6) 124 (1.8) −0.9
Atrial fibrillation 790 (8.1) 716 (7.4) 2.9 216 (3.1) 219 (3.1) −0.2
Ischemic heart disease 2,629 (27.1) 2,619 (27.0) 0.2 698 (9.9) 713 (10.1) −0.7
Peripheral arterial disease 492 (5.1) 464 (4.8) 1.3 148 (2.1) 132 (1.9) 1.6
Hemorrhagic stroke 82 (0.8) 99 (1.0) −1.8 30 (0.4) 29 (0.4) 0.2
Chronic kidney disease 575 (5.9) 535 (5.5) 1.8 482 (6.9) 487 (6.9) −0.3
Severe liver impairment 27 (0.3) 34 (0.4) −1.3 X 5 (0.1) X
Hypothyroidism 658 (6.8) 641 (6.6) 0.7 521 (7.4) 505 (7.2) 0.9
Hyperthyroidism 161 (1.7) 160 (1.6) 0.1 104 (1.5) 103 (1.5) 0.1
Rheumatoid arthritis 166 (1.7) 163 (1.7) 0.2 97 (1.4) 107 (1.5) −1.2
Osteoarthritis 1,862 (19.2) 1,812 (18.7) 1.3 1,242 (17.7) 1,272 (18.1) −1.1
Pre-existing muscle complaints 842 (8.7) 830 (8.6) 0.4 574 (8.2) 571 (8.1) 0.2
Musculoskeletal injuries 2,821 (29.1) 2,843 (29.3) −0.5 2,139 (30.4) 2,139 (30.4) 0.0
COPD 439 (4.5) 446 (4.6) −0.3 228 (3.2) 238 (3.4) −0.8
Macular degeneration 84 (0.9) 82 (0.8) 0.2 37 (0.5) 41 (0.6) −0.8
Falls† 265 (2.7) 256 (2.6) 0.6 175 (2.5) 189 (2.7) −1.3
Pressure ulcer† 54 (0.6) 60 (0.6) −0.8 26 (0.4) 19 (0.3) 1.8
Incontinence† 70 (0.7) 66 (0.7) 0.5 53 (0.8) 59 (0.8) −1.0
Peripheral venous thrombosis† 155 (1.6) 169 (1.7) −1.1 98 (1.4) 100 (1.4) −0.2
Pneumonia† 66 (0.7) 71 (0.7) −0.6 27 (0.4) 33 (0.5) −1.3
Dysphagia† 65 (0.7) 56 (0.6) 1.2 30 (0.4) 34 (0.5) −0.8
Anemia† 207 (2.1) 230 (2.4) −1.6 94 (1.3) 91 (1.3) 0.4
Comedication, n (%)—in the 180 days before the cohort entry date
Fibrates 131 (1.4) 138 (1.4) −0.6 174 (2.5) 175 (2.5) −0.1
Amiodarone 185 (1.9) 157 (1.6) 2.2 21 (0.3) 24 (0.3) −0.8
Systemic corticosteroids 380 (3.9) 400 (4.1) −1.0 215 (3.1) 223 (3.2) −0.7
Antipsychotics 41 (0.4) 39 (0.4) 0.3 44 (0.6) 41 (0.6) 0.6
H2-receptor antagonists 539 (5.6) 531 (5.5) 0.4 196 (2.8) 204 (2.9) −0.7
Benzodiazepines 842 (8.7) 810 (8.3) 1.2 527 (7.5) 520 (7.4) 0.4
Number of cardiovascular drug classes
0 1,760 (18.1) 1,788 (18.4) −0.7 2,240 (31.9) 2,197 (31.2) 1.3
1 to 3 5,807 (59.8) 5,835 (60.1) −0.6 4,063 (57.8) 4,059 (57.7) 0.1
4 to 10 2,136 (22.0) 2,080 (21.4) 1.4 729 (10.4) 776 (11.0) −2.2
Number of general practitioner visits‡, mean (SD) 20.6 (13.4) 20.6 (13.1) −0.1 19.0 (12.2) 19.0 (12.6) 0.3
Hospitalization†, n (%) 2,743 (28.3) 2,787 (28.7) −1.0 1,727 (24.6) 1,717 (24.4) 0.3
Daily statin dose (mg), n (%)
20 (P), 10 (S) 4,405 (45.4) 4,453 (45.9) −1.0 NA NA
40 (P), 20 (S) 5,298 (54.6) 5,250 (54.1) 1.0 NA NA
40 (S), 5 (R), 10 (A) NA NA 695 (9.9) 714 (10.2) −0.9
80 (S), 10 (R), 20 (A) NA NA 6,088 (86.6) 6,069 (86.3) 0.8
20 (R), 40 (A) NA NA 226 (3.2) 228 (3.2) −0.2
40 (R), 80 (A) NA NA 23 (0.3) 21 (0.3) 0.5
Cohort entry date, n (%)
2000–2001 2,912 (30.0) 2,912 (30.0) 0.0 NA NA
2002–2003 4,202 (43.3) 4,202 (43.3) 0.0 1,410 (20.1) 1,410 (20.1) 0.0
2004–2005 1,408 (14.5) 1,408 (14.5) 0.0 3,132 (44.5) 3,132 (44.5) 0.0
2006–2007 321 (3.3) 321 (3.3) 0.0 1,263 (18.0) 1,263 (18.0) 0.0
2008–2009 214 (2.2) 214 (2.2) 0.0 556 (7.9) 556 (7.9) 0.0
2010–2011 246 (2.5) 246 (2.5) 0.0 338 (4.8) 338 (4.8) 0.0
2012–2013 284 (2.9) 284 (2.9) 0.0 144 (2.0) 144 (2.0) 0.0
2014–2015 88 (0.9) 88 (0.9) 0.0 110 (1.6) 110 (1.6) 0.0
2016–2017 28 (0.3) 28 (0.3) 0.0 79 (1.1) 79 (1.1) 0.0
ASD absolute standardized difference, SD standard deviation, X cell contains <5 patients (not shown owing to ethics regulations to preserve
confidentiality), COPD chronic obstructive pulmonary disease, P pravastatin, S simvastatin, R rosuvastatin, A atorvastatin, NA not applicable
*Last record before the cohort entry date
†Assessed in the 3 years before the cohort entry date
‡Assessed in the 1 year before the cohort entry date
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Secondary Prevention Group
After PS matching, we observed an overall HR of 1.04 (95%
CI 0.68–1.59) for pravastatin when compared with simvastat-
in, which decreased to 0.89 (95% CI 0.61–1.30) after applying
the broader outcome definition (Appendix Table 12). In the
PS-matched cohorts of rosuvastatin and simvastatin vs ator-
vastatin, we found an overall HR of 0.93 (95% CI 0.44–1.99)
and 1.43 (95% CI 1.04–1.95), respectively. Broadening the
outcome definition resulted in a HR of 1.13 (95% CI 0.58–
2.22) for rosuvastatin and a HR of 1.29 (95% CI 1.01–1.66)
for simvastatin. The number of events was low in cohorts (iv)
and (v) (Appendix Table 12).
Discussion. Findings of this large primary care database
cohort study do not suggest a systematically reduced risk of
muscular events for hydrophilic statins when compared to
lipophilic statins at comparable lipid-lowering doses. In the
primary prevention study population, results pointed towards a
lower muscular risk for pravastatin (hydrophilic) than simva-
statin (lipophilic) at doses used for the low-intensity statin
therapy, and towards a lower risk of muscular events for
atorvastatin (lipophilic) than rosuvastatin (hydrophilic) and
simvastatin (lipophilic), when compared at doses used for
the moderate- to high-intensity statin therapy. Our results did
not reach statistical significance for all comparisons. However,
point estimates were furthest from the null within the first 90
days after statin initiation, which provides confidence in the
validity of our findings, as statin-associated muscular adverse
events predominately occur within the first 6 months after
treatment start.31
Findings from RCTs comparing statins head-to-head have
suggested a comparable tolerability for hydrophilic and lipo-
philic statins at comparable lipid-lowering doses.11, 12, 32
However, the limited sample size of the trials resulted in a
low absolute number of muscular events. More importantly,
head-to-head RCTs were designed to evaluate statins’ efficacy
Table 2 Censoring Reasons and Duration of Follow-up for the Primary Prevention Cohorts After Propensity Score Matching
Low-intensity statin therapy
Pravastatin 20–40 mg Simvastatin 10–20 mg
N = 9,703 N = 9,703
Censoring reasons, n (%)
Muscular event (outcome) 82 (0.8) 98 (1.0)
Recording of statin intolerance 17 (0.2) 47 (0.5)
Treatment switch 1,287 (13.3) 716 (7.4)
Discontinuation of statin treatment 1,758 (18.1) 1,802 (18.6)
Death 40 (0.4) 26 (0.3)
Recording of an exclusion criterion 198 (2.0) 175 (1.8)
Myocardial infarction or ischemic stroke 283 (2.9) 206 (2.1)
End of study enrollment 6,038 (62.2) 6,633 (68.4)
Duration of follow-up
Mean number of days (standard deviation) 285.0 (112.5) 295.4 (109.1)
Median number of days (interquartile range) 365 (183–365) 365 (212–365)
Moderate- to high-intensity statin therapy
Rosuvastatin 5–40 mg Atorvastatin 10–80 mg
N = 7,032 N = 7,032
Censoring reasons, n (%)
Muscular event (outcome) 100 (1.4) 86 (1.2)
Recording of statin intolerance 20 (0.3) 22 (0.3)
Treatment switch 678 (9.6) 661 (9.4)
Discontinuation of statin treatment 1,408 (20.0) 1,378 (19.6)
Death 8 (0.1) 15 (0.2)
Recording of an exclusion criterion 126 (1.8) 135 (1.9)
Myocardial infarction or ischemic stroke 59 (0.8) 81 (1.2)
End of study enrollment 4,633 (65.9) 4,654 (66.2)
Duration of follow-up
Mean number of days (standard deviation) 292.1 (110.5) 293.7 (108.3)
Median number of days (interquartile range) 365 (205–365) 365 (208–365)
Simvastatin 40–80 mg Atorvastatin 10–20 mg
N = 37,743 N = 37,743
Censoring reasons, n (%)
Muscular event (outcome) 483 (1.3) 368 (1.0)
Recording of statin intolerance 214 (0.6) 166 (0.4)
Treatment switch 3,529 (9.4) 3,156 (8.4)
Discontinuation of statin treatment 7,279 (19.3) 7,526 (19.9)
Death 110 (0.3) 91 (0.2)
Recording of an exclusion criterion 686 (1.8) 651 (1.7)
Myocardial infarction or ischemic stroke 713 (1.9) 467 (1.2)
End of study enrollment 24,729 (65.5) 25,318 (67.1)
Duration of follow-up
Mean number of days (standard deviation) 282.6 (115.4) 287.3 (110.8)
Median number of days (interquartile range) 365 (176–365) 365 (188–365)
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in the reduction of low-density lipoprotein cholesterol and
were not restricted to new statin users. Given that muscular
adverse events typically manifest shortly after statin initia-
tion,31 inclusion of tolerant prevalent statin users may have
resulted in depletion of susceptibles and may have biased
safety results towards the null. For instance, the POLARIS
trial, a double-blind RCT with a 26-week follow-up, included
871 patients with hypercholesterolemia with or without car-
diovascular disease and randomized them to rosuvastatin
40 mg or atorvastatin 80 mg after a dietary run-in period.
The study reported 3.0% (n=13/432) of drug-related myalgia
for rosuvastatin and 3.6% (n=16/439) for atorvastatin. How-
ever, data on the patient characteristics at study entry are
limited and do not provide details on prior statin use.11 The
same is true for the open-label randomized Dutch DIS-
COVERY trial, which included hypercholesterolemic pa-
tients with or without atherosclerotic disease from 152
primary care physician practices. The authors found that
pravastatin 40 mg and simvastatin 20 mg were similarly
well tolerated, with 2.4% (n= 5/211) of pravastatin users
and 1.5% (n= 3/194) of simvastatin users having ad-
verse events of myalgia over 12 weeks of follow-up.
Although the study reported that around 20% of patients
in either treatment group had taken statins in the 4
weeks before enrolment, data on the ever statin use of
patients before this date are not available.12
Table 3 Incidence Rates of the Muscular Events in the Primary Prevention Cohorts Before and After Propensity Score Matching
Number (%) of muscular events Total person-years of follow-up Incidence rate per 1,000
person-years
Exposed Comparator Exposed Comparator Exposed Comparator
Low-intensity statin therapy
Pravastatin vs simvastatin (ref)
Crude 82 (0.8) 2,205 (1.2) 7,584 143,220 10.8 15.4
PS-matched 82 (0.8) 98 (1.0) 7,577 7,852 10.8 12.5
Moderate- to high-intensity statin therapy
Rosuvastatin vs atorvastatin (ref)
Crude 101 (1.4) 854 (1.0) 5,648 64,369 17.9 13.3
PS-matched 100 (1.4) 86 (1.2) 5,628 5,658 17.8 15.2
Simvastatin vs atorvastatin (ref)
Crude 2,456 (1.5) 957 (0.9) 124,546 78,697 19.7 12.2
PS-matched 483 (1.3) 368 (1.0) 29,222 29,708 16.5 12.4
Ref reference, PS propensity score
Table 4 Hazard Ratios for Muscular Events in the Primary Prevention Cohorts Before and After Propensity Score Matching
Hazard ratio (95% CI)
Crude PS-matched
Low-intensity statin therapy
Pravastatin vs simvastatin (ref)
Overall 0.70 (0.56–0.87) 0.86 (0.64–1.16)
Time-specific* (days of follow-up)
1–30 0.41 (0.21–0.80) 0.60 (0.26–1.37)
31–90 0.51 (0.31–0.83) 0.60 (0.32–1.11)
91–180 0.74 (0.48–1.13) 0.97 (0.54–1.74)
181–365 1.02 (0.73–1.44) 1.13 (0.70–1.82)
Moderate- to high-intensity statin therapy
Rosuvastatin vs atorvastatin (ref)
Overall 1.36 (1.11–1.68) 1.17 (0.88–1.56)
Time-specific* (days of follow-up)
1–30 1.44 (0.84–2.46) 1.15 (0.55–2.42)
31–90 1.56 (1.07–2.28) 1.43 (0.82–2.50)
91–180 1.17 (0.75–1.81) 1.24 (0.66–2.31)
181–365 1.33 (0.93–1.90) 0.97 (0.60–1.57)
Simvastatin vs atorvastatin (ref)
Overall 1.62 (1.50–1.75) 1.33 (1.16–1.53)
Time-specific* (days of follow-up)
1–30 1.86 (1.55–2.24) 1.91 (1.29–2.81)
31–90 1.65 (1.43–1.91) 1.46 (1.13–1.88)
91–180 1.57 (1.36–1.82) 1.31 (1.00–1.71)
181–365 1.51 (1.32–1.73) 1.09 (0.86–1.38)
CI confidence interval, PS propensity score, Ref reference
*Patients whose follow-up ended before the time window of interest were excluded from the respective analysis. We censored patients on the day of the
end of the time window of interest in any given analysis
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The former hypothesis of a systematically reduced muscular
risk in association with hydrophilic statins was based on in vitro
data demonstrating a lower cytotoxicity on C2C12 myotubes
for hydrophilic statins than lipophilic statins,10 and in particular
on the consideration that hydrophilic statins penetrate skeletal
muscles less easily due to lower passive diffusion.8 However,
the risk of muscular adverse events of statins may depend on
different pharmacokinetic processes. For instance, statins are
substrates of the organic anion transporting polypeptide
(OATP) transport proteins, which are involved in the hepatic
and muscular uptake of statins.33 It has been discussed that
different statins may bind to these transporters with different
affinities,33, 34 which could eventually lead to different
intramuscular drug concentrations and thus to different risk
profiles for muscular adverse events. In addition, genetic poly-
morphism in the SLCO1B1 gene, which encodes the OATP1B1
hepatic uptake transporter, has been linked to reduced transport
activity and increased plasma statin levels.34, 35 Levels of
simvastatin were found to be particularly affected by the genetic
polymorphism,34 which may explain the elevated muscular risk
for simvastatin observed in the current study. Differences in the
metabolism of statins, i.e., statins’ potential for CYP3A4-
mediated interactions, probably do not explain current findings
given that the results from the sensitivity analysis restricted to
patients without use of CYP3A4 inhibiting drugs were compa-
rable to those from the primary analysis.
Table 5 Hazard Ratios for Subgroup, Sensitivity, and Additional Analyses for Muscular Events in the Primary Prevention Cohorts After
Propensity Score Matching
Number of events Total person-years of follow-
up
HR (95% CI)
Exposed Comparator Exposed Comparator
Low-intensity statin therapy
Pravastatin vs simvastatin (ref)
Subgroup analyses
Male 33 46 3,860 3,938 0.73 (0.47–1.14)
Female 49 51 3,711 3,860 0.99 (0.67–1.47)
40–64 years 39 58 3,903 4,028 0.69 (0.46–1.04)
≥65 years 43 54 3,665 3,743 0.81 (0.54–1.21)
20 vs 10 mg 35 49 3,458 3,562 0.73 (0.47–1.13)
40 vs 20 mg 47 59 4,110 4,258 0.82 (0.56–1.21)
Sensitivity analyses
No muscle complaints before CED 71 98 6,932 7,120 0.74 (0.55–1.01)
No use of CYP3A4 inhibiting drugs* 57 69 5,272 5,463 0.85 (0.60–1.21)
Additional analyses
Censoring if dosage change 75 88 7,034 6,966 0.85 (0.62–1.15)
Broader outcome definition† 99 145 7,577 7,852 0.70 (0.54–0.91)
Moderate- to high-intensity statin therapy
Rosuvastatin vs atorvastatin (ref)
Subgroup analyses
Male 42 36 2,744 2,773 1.18 (0.76–1.84)
Female 57 43 2,862 2,905 1.34 (0.90–1.99)
40–64 years 59 44 3,448 3,478 1.35 (0.92–2.00)
≥65 years 42 23 2,122 2,141 1.84 (1.11–3.06)
5–10 vs 10–20 mg 95 70 5,426 5,490 1.37 (1.01–1.87)
20–40 vs 40–80 mg X 5 188 184 0.59 (0.14–2.47)
Sensitivity analyses
No muscle complaints before CED 88 74 5,179 5,238 1.20 (0.88–1.64)
No use of CYP3A4 inhibiting drugs* 79 63 4,460 4,475 1.26 (0.90–1.75)
Additional analyses
Censoring if dosage change 96 84 5,395 5,196 1.11 (0.83–1.48)
Broader outcome definition† 120 108 5,628 5,658 1.12 (0.86–1.45)
Simvastatin vs atorvastatin (ref)
Subgroup analyses
Male 215 152 14,952 15,144 1.43 (1.16–1.76)
Female 279 204 14,204 14,494 1.39 (1.16–1.67)
40–64 years 251 198 16,280 16,638 1.29 (1.07–1.56)
≥65 years 238 159 12,753 12,910 1.52 (1.24–1.85)
40 vs 10 mg 502 352 28,972 29,517 1.45 (1.27–1.66)
80 vs 20 mg X X 191 197 1.01 (0.20–5.01)
Sensitivity analyses
No muscle complaints before CED 413 287 26,347 26,782 1.46 (1.26–1.70)
No use of CYP3A4 inhibiting drugs* 349 290 21,661 21,932 1.22 (1.04–1.42)
Additional analyses
Censoring if dosage change 468 335 27,920 27,451 1.38 (1.20–1.59)
Broader outcome definition† 697 534 29,222 29,708 1.33 (1.18–1.48)
HR hazard ratio, CI confidence interval, Ref reference, CED cohort entry date, CYP3A4 Cytochrome P450 3A4; X cell contains <5 patients (not shown
owing to ethics regulations to preserve confidentiality)
*The analysis was restricted to patients with no prescription for azole antifungals, macrolide antibiotics, cimetidine, cyclosporine, nefazodone,
amiodarone, amlodipine, diltiazem, and verapamil within 180 days before the cohort entry date. We censored patients on the day of a first prescription
for one of the drugs during follow-up
†Any recorded Read code for “statin intolerance” qualified as an outcome of interest
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In this study, we observed an absolute risk of muscular
events of 1.3% in all new statin users (1.9%when we included
all recordings of statin intolerance). Other observational stud-
ies reported higher risks for patients in the routine care setting;
the PRIMO study, a countrywide survey including 7,924
patients with hyperlipidemia and high-dosage statin therapy
in France, reported an absolute risk of muscular events of
10.5%.36 A cohort study performed in 120 Swedish statin
initiators and with a follow-up of 1 year reported an absolute
risk of 14%.37 Differences in findings may be explained by the
varying data sources and outcome definitions. We defined
muscular events based on Read codes recorded in electronic
primary care records, whereas the PRIMO study conducted
standardized interviews, and the Swedish cohort study used
patient questionnaires to specifically enquire about muscular
symptoms.36, 37 While the latter approaches may have
overestimated the absolute risk of muscular adverse events,
we likely underestimated the absolute risk of muscular events,
as general practitioners may have modified statin treatment
without specifically recording the presumptive adverse event.
However, any such outcome misclassification was most likely
non-differential and thus, if at all, biased HRs towards unity.38
In the comparison of low-intensity statin therapy with prav-
astatin vs simvastatin, more pravastatin users (13.3%) than
simvastatin users (7.4%) were censored due to treatment
switch. The imbalance of censoring reasons may be related
to the intensified target levels for low-density lipoprotein
cholesterol published in the European guidelines in 200339
or the British guidelines in 2005.40 Lower therapeutic targets
have probably caused general practitioners to intensify statin
treatment in patients taking low-intensity statin therapy by
either treatment switch or dosage increase, if higher doses
were available (8.2% of pravastatin vs 14.9% of simvastatin
users were censored due to dosage increase in the additional
censoring analysis). When we restricted the comparison of
pravastatin vs simvastatin to statin users with a CED between
2000 and 2001, i.e., with end of follow-up before 2003, the
comparative muscular risk remained unchanged, but censor-
ing reasons including treatment switch were almost balanced
(Δ<2%) between treatment groups.
Some additional limitations need to be considered. First, small
sample size in the secondary prevention cohorts prevented cal-
culation of reliable risk estimates. We therefore focused on the
study results from the primary prevention cohorts, though we did
present all findings for completeness. Second, the dose ratios at
which statin doses are comparable in efficacy may vary depend-
ing on the literature source. Third, rosuvastatin was the only
study drug that was newly licensed in the UK after 1997, i.e.,
in March 2003.16 If bias due to new drug recording in the
rosuvastatin group had been present, we would have
overestimated the HR of rosuvastatin vs atorvastatin. However,
when we restricted the analysis of rosuvastatin vs atorvastatin to
users with a CED 2 years after licensing of the former, the HR of
muscular events did not change. Fourth, because 98% of our
observed events were related to myalgia and not to myositis or
rhabdomyolysis, reported HRs primarily refer to the risk of mild
statin-associated muscle symptoms. Finally, after PS matching,
baseline characteristics were balanced between treatment groups
compared, but not necessarily between cohorts. Thus, indirect
comparison of the muscular risk of rosuvastatin vs simvastatin,
both used for the moderate- to high-intensity statin therapy, was
not possible.
In conclusion, this study of UK-based primary health care data
does not suggest a systematically reduced risk of muscular events
for hydrophilic statins when compared with lipophilic statins at
comparable lipid-lowering doses. Low-intensity statin therapy
with hydrophilic pravastatin (vs lipophilic simvastatin) and
moderate- to high-intensity statin therapy with lipophilic atorva-
statin (vs hydrophilic rosuvastatin and lipophilic simvastatin)
may be associated with a decreased muscular risk. However,
further studies that will replicate our findings are warranted
before implications for clinical practice are discussed.
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